Talimogene laherparepvec upregulates immune-cell populations in non-injected lesions: findings from a phase II, multicenter, open-label study in patients with stage IIIB-IVM1c melanoma.

Josep Malvehy GuileraIgor SamoylenkoDirk SchadendorfRalf GutzmerJean-Jacques GrobJoseph J SaccoKevin S GorskiAbraham AndersonCheryl A PickettKate LiuHelen Gogas

Published in: Journal for immunotherapy of cancer (2021)

NCT02366195.

Keyphrases

phase ii
open label
clinical trial
phase iii
double blind
phase ii study
study protocol
squamous cell carcinoma
randomized controlled trial
skin cancer